Indivior Pharmaceuticals, Inc.
Key Metrics
- Previous Close
- $35.37
- 52-Week Range
- $27.68 – $42.81
- Market Cap
- $4.28B
- P/E (TTM)
- 10.16
- EPS (TTM)
- 3.57
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- 29.34%
- Gross Margin
- 85.73%
- Operating Margin
- 54.77%
- Profit Margin
- 32.75%
- Current Ratio
- 0.61
- Debt/Equity
- —
- Total Debt
- $501.00M
- Free Cash Flow
- $227.12M
- Revenue Growth
- 13.40%
- Earnings Growth
- 239.40%
- Enterprise Value
- $4.48B
Market Snapshot
About
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to treating substance use disorders and serious mental illnesses. The company's portfolio includes medications for opioid dependence, including buprenorphine-based products marketed under various brand names. Indivior focuses on developing long-acting injectable formulations and abuse-deterrent technologies to improve treatment adherence and patient outcomes. The company combines pharmaceutical development with patient support programs to address the complex challenges of addiction treatment and recovery.